ERBB2 and breast carcinoma: Approximately 50% of HER2-positive disease is also hormone receptor (HR)-positive2, and most cases of HR-positive/HER2-positive (HR+HER2+) breast cancers determined by immunohistochemistry fall into the luminal B subtype based on gene expression3, 4.